Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
- 4 March 2014
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (6) , 1685-1697
Abstract
Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA) with a strong binding affinity and long half-life, has been used in numerous trials for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). We systematically reviewed the efficacy and safety of palonosetron compared to other 5-HT3RAs in CINV prophylaxis.Keywords
This publication has 21 references indexed in Scilit:
- Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapySupportive Care in Cancer, 2013
- The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomitingExperimental and Therapeutic Medicine, 2013
- Update and new trends in antiemetic therapy: the continuing need for novel therapiesAnnals of Oncology, 2010
- Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupportive Care in Cancer, 2010
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trialSupportive Care in Cancer, 2008
- Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in ChildrenArchives of Medical Research, 2008
- A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnnals of Oncology, 2006
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003
- QT interval prolongation predicts cardiovascular mortality in an apparently healthy population.Circulation, 1991